Cell Biotech Co. Ltd
Cell Biotech Co., Ltd., a biotechnology company, develops and sells lactic acid bacteria in South Korea. It also offers probiotic products under the Nutra DUOLAC, LACTOClear, and LAB2PRO brands. The company also exports its products to approximately 40 countries, including the United States, Europe, Japan, and China. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.
Cell Biotech Co. Ltd (049960) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.033x
Based on the latest financial reports, Cell Biotech Co. Ltd (049960) has a cash flow conversion efficiency ratio of 0.033x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.15 Billion) by net assets (₩127.11 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cell Biotech Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Cell Biotech Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cell Biotech Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cell Biotech Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Satellogic Inc. Warrant
NASDAQ:SATLW
|
0.147x |
|
Associated Alcohols & Breweries Ltd.
NSE:ASALCBR
|
0.095x |
|
Deccan Cements Limited
NSE:DECCANCE
|
0.053x |
|
Annehem Fastigheter AB
ST:ANNE-B
|
0.011x |
|
Energisa Mato Grosso - Distribuidora de Energia S/A
SA:ENMT3
|
0.084x |
|
Méliuz S.A
SA:CASH3
|
0.012x |
|
BINHAI INVESTM.CO. HD-10
F:WS7A
|
N/A |
|
Kyungdong City Gas Co Ltd
KO:267290
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Cell Biotech Co. Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Cell Biotech Co. Ltd from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩124.17 Billion | ₩19.27 Billion | 0.155x | +122.14% |
| 2023-12-31 | ₩111.89 Billion | ₩7.82 Billion | 0.070x | -41.08% |
| 2022-12-31 | ₩108.09 Billion | ₩12.81 Billion | 0.119x | -15.07% |
| 2021-12-31 | ₩106.69 Billion | ₩14.89 Billion | 0.140x | +45.93% |
| 2020-12-31 | ₩99.98 Billion | ₩9.56 Billion | 0.096x | -3.14% |
| 2019-12-31 | ₩103.60 Billion | ₩10.23 Billion | 0.099x | -25.37% |
| 2018-12-31 | ₩105.62 Billion | ₩13.98 Billion | 0.132x | -47.02% |
| 2017-12-31 | ₩90.20 Billion | ₩22.53 Billion | 0.250x | +16.83% |
| 2016-12-31 | ₩84.15 Billion | ₩17.99 Billion | 0.214x | -19.39% |
| 2015-12-31 | ₩68.76 Billion | ₩18.24 Billion | 0.265x | +40.17% |
| 2014-12-31 | ₩52.36 Billion | ₩9.91 Billion | 0.189x | -9.37% |
| 2013-12-31 | ₩43.05 Billion | ₩8.99 Billion | 0.209x | +23.25% |
| 2012-12-31 | ₩36.42 Billion | ₩6.17 Billion | 0.169x | -1.36% |
| 2011-12-31 | ₩31.77 Billion | ₩5.45 Billion | 0.172x | -- |